



Attn: Trading and Market Making / Legal and Compliance / Operations / Systems
UNIFORM PRACTICE ADVISORY (UPC #16-19) 05/02/2019
Synergy Pharmaceuticals, Inc. (SGYPQ)

Notice has been received that the above Company's Modified Fourth Amended Joint Plan of Reorganization, as Modified became effective on 05/01/2019. Pursuant to the Plan, on the Effective Date, the existing Equity Interests in Synergy Pharmaceuticals, Inc. will be cancelled and there will be no distribution to holders.

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.